This DAlessio_GLP-1Insulin_Readme.txt file was generated on 2022-01-25 by David D'Alessio


GENERAL INFORMATION

1. Title of Dataset: Data from: GLP-1 receptor blockade reduces stimulated insulin secretion in fasted subjects with low circulating GLP-1

2. Author Information
	A. Primary Contact Information
		Name: David D'Alessio
		Institution: Duke University
		Phone: 919-684-5778
		ORCID: 0000-0003-4155-4870

3. Date of data collection (single date, range, approximate date) <suggested format YYYY-MM-DD>: Jan 2016-Dec 2019

4. Geographic location of data collection <latitude, longitude, or city/region, State, Country, as appropriate>: Duke University

5. Information about funding sources that supported the collection of the data: Merck investigator initiated research program; NIH NIDDK R01-101991


SHARING/ACCESS INFORMATION

1. Licenses/restrictions placed on the data: CC0 waiver (http://creativecommons.org/publicdomain/zero/1.0/)

2. Links to publications that cite or use the data: Paper in revision

3. Links to other publicly accessible locations of the data: no

4. Links/relationships to ancillary data sets: no

5. Was data derived from another source? no
	
6. Recommended citation for this dataset: D'Alessio, D., Gray, S., Hoselton, A., Krishna, R., Slentz, C. (2022). Data from: GLP-1 receptor blockade reduces stimulated insulin secretion in fasted subjects with low circulating GLP-1. Duke Research Data Repository. https://doi.org/10.7924/r4ks6tf5q


DATA & FILE OVERVIEW

1. File List: 
	a) ValidationGlucagonAssay- Performance and testing characteristics of Ansh glucagon ELISA
	b) ValidationGLP-1Assay- Performance and testing characteristics of Ansh GLP-1 ELISA
	c) GlucoseHormoneValues- plasma concentrations of glucose, insulin, C-peptide, glucagon and GLP-1 for subjects enrolled in the study
	d) jc2021-02246_Supplement- Seven supplemental tables and two supplemental figures accompanying primary paper.

2. Relationship between files, if important: n/a

3. Additional related data collected that was not included in the current data package: n/a

4. Are there multiple versions of the dataset? no
	

DATA-SPECIFIC INFORMATION FOR: GlucoseHormoneValues

   *Subjects are listed by number on the y-axis. Nondiabetic subjects (here labeled Healthy and Treatment-group 1) and Diabetic subjects (here labeled T2DM and Treatment-group 2).

   *Study visits are divided into those for which the subject received sitagliptin (Sita) or placebo (PBO), and the order of the studies in the column Visits as first (1) or second (2).

   *Each visit (Sita or PBO) is divided into 3 periods (0, 1, 2). Period 0 includes only the fasting glucose concentration (mg/dl) taken before treatment (Sita or PBO) was administered. No hormone concentrations were measured at this timepoint.

   *Period 1 refers to the time before and after acute arginine infusion with Ex9 treatment; Period 2 refers to the time before and after arginine infusion with saline treatment.

For each treatment period there are 19 computed outcomes: 

	1.  gluc_BL- mean glucose (mg/dl) in the 20 minutes before arginine was administered. 
	2.  gluc_avg10- mean glucose (mg/dl) in the 10 minutes immediately after arginine was administered.
	3.  ins-BL- mean plasma insulin (pmol/L) in the 20 minutes before arginine was administered.
	4.  ins-10avg- mean of the 5 insulin measurements made in the 10 minutes immediately after arginine was administered.
	5.  ins_10AUC- area above baseline insulin of the curve of insulin values in the 10 minutes immediately after arginine was administered.
	6.  cpep-BL- mean plasma C-peptide (pmol/L) in the 20 minutes before arginine was administered.
	7.  cpep-10avg- mean of the 5 C-peptide measurements made in the 10 minutes immediately after arginine was administered.
	8.  cpep_10AUC- area above baseline C-peptide of the curve of insulin values in the 10 minutes immediately after arginine was administered.
	9.  gcg-BL- mean plasma glucagon (pmol/L) in the 20 minutes before arginine was administered.
	10. gcg-10avg- mean of the 5 glucagon measurements made in the 10 minutes immediately after arginine was administered.
	11. gcg_10AUC- area above baseline glucagon of the curve of insulin values in the 10 minutes immediately after arginine was administered.
	13. glp1-BL- mean plasma GLP-1 (pmol/L) in the 20 minutes before arginine was administered.
	14. glp1-10avg- mean of the 5 GLP-1 measurements made in the 10 minutes immediately after arginine was administered.
	15. glp1_10AUC- area above baseline GLP-1 of the curve of insulin values in the 10 minutes immediately after arginine was administered.

Plasma glucagon and GLP-1 were only measured in subsets of nondiabetic and diabetic subjects. Missing values for these analytes represent samples not assayed.